Diabetes, Vol 35, Issue 8 894-898, Copyright © 1986 by American Diabetes Association

ARTICLES

Are insulin autoantibodies markers for insulin-dependent diabetes mellitus?

MA Atkinson, NK Maclaren, WJ Riley, WE Winter, DD Fisk and RP Spillar

Recent studies have shown that insulin autoantibodies occur in patients with newly diagnosed insulin-dependent diabetes mellitus (IDDM) before exogenous insulin treatment. Our study was designed to test the hypothesis that insulin autoantibodies, like cytoplasmic islet cell antibodies (ICAs), can identify individuals with ongoing autoimmune beta-cell destruction and increased risk of IDDM development. Insulin autoantibodies detected by use of a radioligand-binding assay were found in 1.4% of normal controls, 4% of first-degree relatives of IDDM patients, and in 37% of newly diagnosed IDDM patients. A strong positive correlation between insulin autoantibodies and ICAs was observed. HLA typing of insulin-autoantibody-positive first-degree relatives of IDDM patients, as well as in the general population, revealed a strong association with HLA-DR3 and/or-DR4, suggesting that insulin autoantibodies are restricted to persons genetically susceptible to IDDM. In an ongoing study of beta-cell function in ICA-positive nondiabetic individuals, the additional presence of insulin autoantibodies significantly increased the likelihood of beta-cell dysfunction. After intravenous glucose stimulation, insulinopenia was present in 70% of ICA and insulin-autoantibody-positive individuals in contrast to only 23% of ICA-positive, insulin-autoantibody-negative persons. These data document a significant association between insulin autoantibodies and ICAs and support the contention that insulin autoantibodies, like ICAs, are markers of ongoing beta-cell destruction.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Diabetes Care, January 1, 2003; 26(90001): s5 - 20. [Full Text] [PDF]

				W. E. Winter, N. Harris, and D. Schatz Immunological Markers in the Diagnosis and Prediction of Autoimmune Type 1a Diabetes Clin. Diabetes, October 1, 2002; 20(4): 183 - 191. [Abstract] [Full Text] [PDF]

				L. Virag and C. Szabo The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors Pharmacol. Rev., September 1, 2002; 54(3): 375 - 429. [Abstract] [Full Text] [PDF]

				Kukreja Autoimmunity and Diabetes J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4371 - 4378. [Abstract] [Full Text]

				M. A. Atkinson and N. K. Maclaren The Pathogenesis of Insulin-Dependent Diabetes Mellitus N. Engl. J. Med., November 24, 1994; 331(21): 1428 - 1436. [Full Text]